Case scenario: Emergency reversal of oral anticoagulation

Anesthesiology

Volumn 113, Issue 5, 2010, Pages 1192-1197

  Koutrouvelis, Aristides ^a   Abouleish, Amr ^a   Indrikovs, Alexander ^a   Alperin, Jack ^b  

^a Blood Blank ^*  (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9 COMPLEX; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES;

AGED; ANTICOAGULATION; ARTICLE; CASE REPORT; EMERGENCY TREATMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; CHEMICALLY INDUCED; ORAL DRUG ADMINISTRATION; POSTOPERATIVE HEMORRHAGE; PROCEDURES;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; EMERGENCY TREATMENT; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; POSTOPERATIVE HEMORRHAGE;

EID: 78049331514     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181f7a7a3     Document Type: Article

References (32)

1. Yasaka M, Sakata T, Minematsu K, Naritomi H: Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002; 108:25-30
2. Ozgonenel B, O'Malley B, Krishen P, Eisenbrey AB: Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007; 82:1091-4
3. Grifols Biologicals, Inc. Manufacturer's Description and Guidelines for Factor IX Complex Profilnine SD, Solvent Detergent Treated. Grifols Biologicals, Inc. Los Angeles, CA
4. Pérez-Andreu V, Roldán V, Gonźalez-Conejero R, Hernán-dez-Romero D, Vicente V, Marín F: Implications of phar-macogenetics for oral anticoagulants metabolism. Curr Drug Metab 2009; 10:632-42
5. Souri M, Iwata H, Zhang WG, Ichinose A: Unique secretion mode of human protein Z: Its Gla domain is responsible for inefficient, vitamin K-dependent and warfarin-sensitive secretion. Blood 2009; 113:3857-64
6. Lavítola Pde L, Spina GS, Sampaio RO, Tarasoutchi F, Grinberg M: Bleeding during oral anticoagulant therapy: Warning against a greater hazard. Arq Bras Cardiol 2009; 93:174-9
7. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE: A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115:145-9
8. Tanaka KA, Szlam F, Dickneite G, Levy JH: Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced antico-agulation. Thromb Res 2008; 122:117-23
9. Lechler E: Use of prothrombin complex concentrates for prophylaxis and treatment of bleeding episodes in patients with hereditary deficiency of prothrombin, factor VII, factor X, protein C protein S, or protein Z. Thromb Res 1999; 95:S39-50
10. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM: Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4:967-70
11. Dargaud Y, Desmurs-Clavel H, Marin S, Bordet JC, Poplavsky JL, Negrier C: Comparison of the capacities of two prothrombin complex concentrates to restore throm-bin generation in plasma from orally anticoagulated patients: An in vitro study. J Thromb Haemost 2008; 6:962-8
12. Cundiff DK: Clinical evidence for rebound hypercoagula-bility after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med 2008; 10:258
13. Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J: Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998; 79:1116-8
14. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM, Warfarin Reversal Consensus Group: Warfarin reversal: Consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181:492-7
15. Pabinger I, Tiede A, Kalina U, Knaub S, Germann R, Os-termann H, Beriplex P/N Anticoagulation Reversal Study Group: Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: A prospective clinical trial of emergency anticoagulation reversal. Ann Hematol 2010; 89:309-16
16. Frazee LA, Bourguet CC, Gutierrez W, Elder-Arrington J, Elackattu AE, Haller NA: Retrospective evaluation of a method to predict fresh-frozen plasma dosage in anticoag-ulated patients. Am J Ther 2008; 15:111-8
17. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM, British Committee for Standards in Haematology, Blood Transfusion Task Force: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11-28
18. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R: Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49:1171-7
19. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S-98S
20. CSL Limited. Guidelines for Use of Prothrombinex-HT. CSL Limited, Parkville, Victoria, Australia 2010
21. Crowther MA, Warkentin TE: Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: Focus on new anticoagulant agents. Blood 2008; 111:4871-9
22. Vigué B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, Martin L, Benhamou D: Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33:721-5
23. Vigue B: Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage\-from theory to practice. Crit Care 2009; 13:209
24. Demeyere R, Gillardin S, Arnout J, Strengers PF: Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: A randomized study. Vox Sang 2010; 99:251-60
25. Kalainov DM, Valentino LA: Recombinant activated factor VII as a temporary reversal agent for warfarin anticoagu-lation: A cautionary report on an off-label application. Am J Orthop 2008; 37:572-4
26. Taketomi T, Szlam F, Levy JH, Tanaka KA: Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis 2008; 19:106-8
27. Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG Jr, Czervionke LF, Meschia JF: Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intra-cranial hemorrhage. Mayo Clin Proc 2004; 79:1495-500
28. Howes JL, Smith RS, Helmer SD, Taylor SM: Complications of recombinant activated human coagulation factor VII. Am J Surg 2009; 198:895-9
29. McMullin NR, Wade CE, Holcomb JB, Nielsen TG, Rossaint R, Riou B, Rizoli SB, Kluger Y, Choong PI, Warren B, Tortella BJ, Boffard KD; NovoSeven Trauma Study Group: Prolonged pro-thrombin time after recombinant activated factor VII therapy in critically bleeding trauma patients is associated with adverse outcomes. J Trauma 2010; 69:60-9
30. Dickneite G, Dörr B, Kaspereit F, Tanaka KA: Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. Trauma 2010; 68:1151-7
31. Chen HY, Ding QL, Zhang LW, Xu GQ, Dai J, Wang XF, Xi XD, Wang HL: The application of thrombin generation tests to warfarin anticoagulation monitoring. Zhonghua Xue Ye Xue Za Zhi 2008; 29:168-70
32. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME: Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010; 116:693-701